Background: Postmenopausal early breast cancer patients, treated with endocrine therapy, have approximately 90% five year disease free survival (DFS). However, for patients at higher risk of relapse, additional adjuvant chemotherapy may be indicated. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers to stratify patients on tamoxifen (T) therapy into various risk groups potentially guiding treatment choices. We tested the efficacy of this panel in the TEAM trial (exemestane (E) versus T→E) to determine the relevance in patients treated with an AI. Patients & Methods: Pathology blocks from 4598 TEAM patients were collected and tissue microarrays constructed. The cohort overall was 47% node positive, and 36% also received adjuvant chemotherapy. Samples were stained, using triplicate 0.6mm2 TMA cores, and positivity for p53, HTF9C, CEACAM5, NDRG1, SLC7A5 assessed. Each case was assigned a Mammostrat risk score and analysed for disease free survival (DFS) by marker positivity and risk score. Results: Preliminary results on the UK TEAM cohort (1059 cases) showed 18.9% stained positive for p53 (184/972), 21.3% for NRDG1 (204/956), 26.4% for SLC7A (253/957), 21.9% for HTF9C (220/1004), 18.3% for CEACAM5 (185/1009). Complete data was available for 919 cases including patients treated with chemotherapy, with 447 (49%) designated low risk, 213 (23%) medium and 259 (28%) high risk. In univariate analysis, Mammostrat scores were prognostic (p=0.02), with 5 year DFS (see comment above) results being 86.9±1.7%, 80.1±3.0% and 80.8±2.6% for patients with low, medium and high Mammostrat scores respectively. Analyses on the entire TEAM pathology cohort are ongoing, and further data with sufficient power to evaluate the impact of Mammostrat in multivariate regression analyses will be presented. Conclusion: Preliminary analysis of the impact of the Mammostrat score in both tamoxifen and exemestane treated patients suggests it retains its prognostic value in this context. Further analysis with the power to evaluate the impact of Mammostrat in multivariate regression analyses will be presented. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-10-33.
Molecular profiling has suggested that ER+/HER2+ breast cancer is a distinct entity from ER-/HER2+ breast cancer and confers a worse prognosis in systemically untreated patients. It has recently been reported that genes associated with PI3K/AKT pathway activation predict pathologic complete response in patients receiving trastuzumab-chemotherapy in ER+/HER+ but not in ER-/HER2+ tumors. Past studies have indicated that 30-40% of breast cancers harbor a PI3K mutation, predominantly in exons 9 and 20. We analyzed 100 HER2+ breast cancers stratified by ER status to confirm the differing level of HER2 mRNA expression relative to ER status and to determine the association, in any, to the presence of a PI3K mutation. Methods: Fifty ER+ and 50 ER-breast cancers previously assessed as HER2+ (HER2:CEP-17 ratio ranging from 2.40-16.20, PathVysion Kit, Abbott) were pulled from the archives. ER was assessed by IHC, (6F11, NovaCastra) using a clinically validated method in accordance with the new CAP/ASCO guidelines. Molecular analysis was performed on paraffin embedded tissues. Tumor areas of interest were identified and selectively removed from the section. RNA and DNA were isolated from the collected tissue. Real-time quantitative RT-PCR was used to evaluate the expression of the HER2 gene from the RNA fraction. The expression values were calculated as a ratio of HER2 to the reference gene. The DNA was added to an allele specific PCR to assess 7 of the most common mutations in exons 9 and 20 of the PI3K gene. All data was generated on an AB 7900 HT real-time platform. Results: Quantitative HER2 mRNA Results Discusssion: The level of HER2 mRNA expression differs significantly based on the expression of ER. This is further accentuated by the presence of a PI3K mutation, increasing the level of HER2 mRNA expression is ER-patients and decreasing the level of HER2 mRNA expression in ER+ patients. This observation needs to be further explored and may have profound implications, if as current data suggests, the subset of patients most responsive to trastuzumab therapy are the ER+, PI3K activated tumors. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-06-12.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.